Additions to Methotrexate with Conventional and Biologic DMARDs in Rheumatoid Arthritis: Are there Difference in Subsequent Time to Treatment Failure?

被引：0

作者：

Moura, Cristiano ^{[1
]}

Bykerk, Vivian ^{[2
]}

Schieir, Orit

Valois, Marie-France ^{[3
]}

Bartlett, Susan ^{[3
]}

Hitchon, Carol ^{[4
]}

Pope, Janet ^{[5
]}

Boire, Gilles ^{[6
]}

Haraoui, Boulos ^{[7
]}

Keystone, Edward ^{[8
]}

Tin, Diane ^{[9
]}

Thorne, Carter ^{[9
]}

Bernatsky, Sasha ^{[10
]}

机构：

[1] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada

[2] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA

[3] McGill Univ, Montreal, PQ, Canada

[4] Univ Manitoba, Winnipeg, MB, Canada

[5] Western Univ, Dept Med, Div Rheumatol, London, ON, Canada

[6] Univ Sherbrooke, Sherbrooke, PQ, Canada

[7] Inst Rhumatol Montreal, Montreal, PQ, Canada

[8] Univ Toronto, Mt Sinai Hosp, Toronto, ON, Canada

[9] Southlake Reg Hlth Ctr, Newmarket, Suffolk, England

[10] McGill Univ, Ctr Hlth, Montreal, PQ, Canada

来源：

JOURNAL OF RHEUMATOLOGY | 2018年 / 45卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1004 / 1004

页数：1

共 50 条

[11] Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs
Strangfeld, A.
Richter, A.
Siegmund, B.
Herzer, P.
Rockwitz, K.
Demary, W.
Aringer, M.
Meissner, Y.
Zink, A.
Listing, J.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (03) : 504 - 510
[12] Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients
Karadeniz, Hazan
Cindil, Emetullah
Babaoglu, Hakan
Guler, Aslihan Avanoglu
Salman, Reyhan Bilici
Satas, Hasan
Atas, Nuh
Goker, Berna
Haznedaroglu, Seminur
Ozturk, Mehmet Akif
Tufan, Abdurrahman
EUROPEAN JOURNAL OF RHEUMATOLOGY, 2022, 9 (02) : 75 - 81
[13] REVIEW OF ECONOMIC MODELS FOR THE EVALUATION OF BIOLOGIC DMARDS IN RHEUMATOID ARTHRITIS
Van Laer, J.
Gubbels, L.
Rodriguez, I. L.
Maervoet, J.
Nijhuis, T.
Nielsen, A. T.
Peterson, S.
Hemels, M.
Ganguly, R.
VALUE IN HEALTH, 2015, 18 (07) : A696 - A696
[14] BUDGET IMPACT ANALYSIS OF THE INCLUSION OF TOFACITINIB AS AN ALTERNATIVE FOR RHEUMATOID ARTHRITIS TREATMENT AFTER CONVENTIONAL DMARDS FAILURE IN CHILE
Gutierrez-Ardila, M., V
VALUE IN HEALTH, 2016, 19 (03) : A228 - A229
[15] Patient compliance in the treatment of rheumatoid arthritis with biologic DMARDs and predicting factors: A literature review
Schmidt, E
Keilhorn, A
VALUE IN HEALTH, 2005, 8 (06) : A29 - A29
[16] Methotrexate for the treatment of rheumatoid arthritis in the biologic era: Still an "anchor" drug?
Favalli, Ennio Giulio
Biggioggero, Martina
Meroni, Pier Luigi
AUTOIMMUNITY REVIEWS, 2014, 13 (11) : 1102 - 1108
[17] Efficacy and Safety of Methotrexate in Combination with Other Non-biologic Disease-modifying Antirheumatic Drugs (DMARDs) in Treatment of Rheumatoid Arthritis
Castrejon, Isabel
Gibson, Kathryn A.
Pincus, Theodore
BULLETIN OF THE HOSPITAL FOR JOINT DISEASES, 2013, 71 : S20 - S28
[18] EFFICACY OF BIOLOGIC DMARDS IN DEPRESSIVE SYMPTOMS IN PATIENTS WITH RHEUMATOID ARTHRITIS
Ng, K. J.
Huang, K-Y
Tung, C-H
Lu, M-C
Lai, N-S
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 301 - 301
[19] THE IMPACT OF AGE ON DISCONTINUATION OF BIOLOGIC DMARDs IN PATIENTS WITH RHEUMATOID ARTHRITIS
Rivera Teran, V.
Sicsik, S.
Vega-Morales, D.
Irazoque-Palazuelos, F.
Miranda, D.
Casasola, J. C.
Carrilo, S.
Pena, A.
Castillo Ortiz, A.
Munoz-Monroy, O. E.
Duran Barragan, S.
Paz, A.
Torres Valdez, E.
Valdes Corona, L. F.
Xibille Friedmann, D. X.
Zamora, E.
Ramos, A.
Santana, N.
Vazquez, M.
Guerrero, F.
Zepeda, C.
Alvarado, K.
Rivera, M.
Alpizar-Rodriguez, D.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 559 - 560
[20] CHANGES IN LYMPHOCYTIC SUBSETS IN RHEUMATOID ARTHRITIS TREATED WITH BIOLOGIC DMARDS
Novella-Navarro, M.
Cabrera-Alarcon, J. L.
Munoz-Gomez, M. M.
Pavo-Blanco, M.
Salvatierra-Ossorio, J.
Raya-Alvarez, E.
OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S169 - S169

← 1 2 3 4 5 →